Jacobs Levy Equity Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Jacobs Levy Equity Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,312	Closed	-$29K	–	1204
2020 Q1	$29K	Buy	+10,312	New	+$33.2K	﹤0.01%	989
2018 Q1	–	Sell	-52,800	Closed	-$145K	–	1128
2017 Q4	$145K	Sell	52,800 -200	-0.4%	-$614	﹤0.01%	933
2017 Q3	$180K	Buy	+53,000	New	+$147K	﹤0.01%	880
2016 Q3	–	Sell	-836,862	Closed	-$2.63M	–	1252
2016 Q2	$2.63M	Sell	836,862 -427,817	-34%	-$1.43M	0.05%	371
2016 Q1	$4.21M	Buy	+1,264,679	New	+$3.94M	0.09%	250
2015 Q3	–	Sell	-10,800	Closed	-$69K	–	930
2015 Q2	$69K	Hold	10,800	–	–	﹤0.01%	777
2015 Q1	$76K	Buy	+10,800	New	+$78.2K	﹤0.01%	754
2013 Q4	–	Sell	-75,900	Closed	-$605K	–	1135
2013 Q3	$605K	Buy	+75,900	New	+$610K	0.01%	643

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Jacobs Levy Equity Management's PDLI Position: Q2 2020 in Review

Jacobs Levy Equity Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2020, closing a stake of 10,312 shares — an estimated $29K sold.

Jacobs Levy Equity Management first reported a position in PDLI in Q3 2013 and held it in 8 quarters. The position peaked at $4.21M in Q1 2016. 136 funds tracked by Wall St. Rank hold PDLI as of Q2 2020.

Jacobs Levy Equity Management reported no remaining PDL BioPharma, Inc. position as of Q2 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 10,312 PDL BioPharma, Inc. shares in Q2 2020, an estimated $29K.
Jacobs Levy Equity Management first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 8 quarters.
Jacobs Levy Equity Management's PDL BioPharma, Inc. position peaked at $4.21M in Q1 2016.
136 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2020, filed 17 Aug 2020.